Following the 2023 FDA approval of Casgevy and Lyfgenia, gene therapies offer new hope for severe sickle cell disease, which can shorten life expectancy by 20 years. However, high costs, complex procedures, and limited specialized centers hinder access for thousands of patients, notes Dr. Edward Don